PRESS RELEASE published on 03/18/2024 at 08:05, 6 months 1 day ago BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps BioNxt Solutions Inc. reports progress in toxicity and PK studies, advancing towards human comparative bioavailability studies. Development includes technology transfer, upscaling, & clinical sample prep for bioequivalence study BioNxt Solutions Inc. Toxicity Studies Comparative Pharmacokinetic Studies Bioavailability Pharmaceutical Drug Market
BRIEF published on 03/13/2024 at 08:10, 6 months 6 days ago BioNxt Reports Promising Results in ODF Cladribine Study for MS BioNxt Solutions Inc. Multiple Sclerosis Cladribine Pharmacokinetic Study Drug Delivery Technology
BRIEF published on 03/13/2024 at 08:10, 6 months 6 days ago BioNxt rapporte des résultats prometteurs dans l'étude ODF Cladribine pour la SEP BioNxt Solutions Inc. Sclérose En Plaques Cladribine Étude Pharmacocinétique Technologie D'administration De Médicaments
PRESS RELEASE published on 03/13/2024 at 08:05, 6 months 6 days ago BioNxt Reports Successful Results From ODF Cladribine PK Study BioNxt Solutions Inc. announces successful completion of comparative pharmacokinetic study for its oral dissolvable film Cladribine product for Multiple Sclerosis treatment, demonstrating rapid absorption similar to reference drug BioNxt Solutions Inc. Multiple Sclerosis Cladribine Pharmacokinetic Study Drug Delivery System
PRESS RELEASE published on 02/17/2024 at 01:50, 7 months 2 days ago BioNxt Solutions Finalizes Agreement BioNxt Solutions Inc. finalizes Settlement Agreement with a creditor to settle $282,415 debt through issuance of common shares and a cash payment. Debt to be settled in three instalments of shares based on market price Common Shares Debt Settlement BioNxt Solutions Inc. Settlement Agreement Creditor
PRESS RELEASE published on 01/30/2024 at 05:48, 7 months 20 days ago BIONXT SOLUTIONS ANNOUNCES CLOSING OF FINAL TRANCHE OF NON-BROKERED PRIVATE PLACEMENT BioNxt Solutions Inc. closes final tranche of non-brokered private placement, raising gross proceeds of $288,000 to fund drug development and working capital purposes Private Placement Working Capital Investment Drug Development BioNxt Solutions Inc.
PRESS RELEASE published on 12/22/2023 at 09:05, 8 months 28 days ago BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing
PRESS RELEASE published on 12/22/2023 at 01:50, 8 months 28 days ago BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing
PRESS RELEASE published on 12/12/2023 at 09:05, 9 months 7 days ago BioNxt Receives Delivery of Premium Commercial Coating and Cutting Equipment for Commercial Manufacturing of Drug Delivery Products
PRESS RELEASE published on 12/09/2023 at 04:30, 9 months 10 days ago BioNxt Solutions Announces Completion of Debenture and Interest Settlement and Issuance of Finder’s Warrants
Published on 09/19/2024 at 23:15, 1 hour 1 minute ago Cypher Metaverse Inc. Announces Second Closing of Financing
Published on 09/19/2024 at 23:00, 1 hour 16 minutes ago WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Published on 09/19/2024 at 20:15, 4 hours 1 minute ago Living Security Named a Leader in Human Risk Management, Closely Watched Tech Industry Report
Published on 09/19/2024 at 21:09, 3 hours 6 minutes ago EQS-Adhoc: Mercedes-Benz Group AG adjusts full-year guidance for the year 2024 based on current market outlook
Published on 09/19/2024 at 18:44, 5 hours 31 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/19/2024 at 18:03, 6 hours 13 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 09/19/2024 at 17:52, 6 hours 23 minutes ago PILOT 28 : FIGEAC AÉRO remporte 3 nouveaux contrats sur l'A320 pour 65 millions d'euros
Published on 09/19/2024 at 17:52, 6 hours 23 minutes ago PILOT 28: FIGEAC AÉRO secures 3 new wins on the A320 airframe for 65 million euros
Published on 09/19/2024 at 17:45, 6 hours 31 minutes ago Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Published on 09/19/2024 at 17:45, 6 hours 31 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Published on 09/19/2024 at 17:45, 6 hours 31 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)